Baseline characteristics of the patients*
| Placebo | Infliximab 5 mg/kg | |
|---|---|---|
| *Results are shown as mean (SD) unless otherwise stated. | ||
| Patients randomised (n) | 100 | 100 |
| Female sex (%) | 49 | 29 |
| Age (years) | 46.5 (11.3) | 47.1 (12.8) |
| PsA subtype (%) | ||
| Arthritis involving distal interphalangeal joints | 23 | 26 |
| Arthritis mutilans | 2 | 1 |
| Asymmetric peripheral arthritis | 22 | 18 |
| Polyarticular arthritis | 47 | 53 |
| Spondylitis with peripheral arthritis | 6 | 2 |
| PsA duration (years) | 7.5 (7.8) | 8.4 (7.2) |
| ACR component | ||
| Number of swollen joints (0–66) | 14.4 (8.9) | 13.9 (7.9) |
| Number of tender joints (0–68) | 25.1 (13.3) | 24.6 (14.1) |
| CRP (mg/l) | 23 (34) | 19 (21) |
| Physician’s global assessment of disease activity (VAS; 0–10 cm) | 5.9 (1.7) | 5.5 (1.8) |
| Patient’s global assessment of disease activity (VAS; 0–10 cm) | 5.9 (2.2) | 5.4 (2.1) |
| Patient’s assessment of pain (VAS; 0–10 cm) | 5.9 (2.3) | 5.6 (2.1) |
| HAQ disability index (0–3) | 1.1 (0.6) | 1.1 (0.6) |
| Duration of morning stiffness (0–1440 min) | 183.4 (308.8) | 216.0 (376.0) |
| Patients with 1 or more dactylitis digits (%) | 41 | 40 |
| Patients with enthesopathy (%) | 35 | 42 |
| Psoriasis evaluation | ||
| Patients with ⩾3% BSA affected with psoriasis (%) | 87 | 83 |
| PASI score (0–72) | 10.2 (9.0) | 11.4 (12.7) |
| Target lesion score (0–12) | 6.2 (1.9) | 5.9 (2.2) |
| SF-36 score | ||
| Physical component (0–100) | 31.0 (9.0) | 33.0 (9.4) |
| Mental component (0–100) | 47.0 (11.9) | 45.5 (11.9) |
| Baseline drug | ||
| Patients taking MTX (%) | 45 | 47 |
| Patients taking oral corticosteroids (%) | 10 | 15 |
| Patients taking NSAIDs (%) | 73 | 71 |